Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 264

1.

Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung.

Ueda T, Aokage K, Nishikawa H, Neri S, Nakamura H, Sugano M, Tane K, Miyoshi T, Kojima M, Fujii S, Kuwata T, Ochiai A, Kusumoto M, Suzuki K, Tsuboi M, Ishii G.

J Cancer Res Clin Oncol. 2018 Feb 12. doi: 10.1007/s00432-018-2602-z. [Epub ahead of print]

PMID:
29435735
2.

A secondary RET mutation in the activation loop conferring resistance to vandetanib.

Nakaoku T, Kohno T, Araki M, Niho S, Chauhan R, Knowles PP, Tsuchihara K, Matsumoto S, Shimada Y, Mimaki S, Ishii G, Ichikawa H, Nagatoishi S, Tsumoto K, Okuno Y, Yoh K, McDonald NQ, Goto K.

Nat Commun. 2018 Feb 12;9(1):625. doi: 10.1038/s41467-018-02994-7.

3.

Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.

Nakamura H, Ichikawa T, Nakasone S, Miyoshi T, Sugano M, Kojima M, Fujii S, Ochiai A, Kuwata T, Aokage K, Suzuki K, Tsuboi M, Ishii G.

Lung Cancer. 2018 Jan;115:56-63. doi: 10.1016/j.lungcan.2017.11.013. Epub 2017 Nov 20.

PMID:
29290263
4.

Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non-Small Cell Lung Cancer.

Aokage K, Miyoshi T, Ishii G, Kusumoto M, Nomura S, Katsumata S, Sekihara K, Tane K, Tsuboi M.

J Thorac Oncol. 2017 Dec 13. pii: S1556-0864(17)33080-0. doi: 10.1016/j.jtho.2017.11.129. [Epub ahead of print]

PMID:
29246833
5.

Immunohistochemical and genetic characteristics of lung cancer mimicking organizing pneumonia.

Ichikawa T, Saruwatari K, Mimaki S, Sugano M, Aokage K, Kojima M, Hishida T, Fujii S, Yoshida J, Kuwata T, Ochiai A, Suzuki K, Tsuboi M, Goto K, Tsuchihara K, Ishii G.

Lung Cancer. 2017 Nov;113:134-139. doi: 10.1016/j.lungcan.2017.10.001. Epub 2017 Oct 5.

PMID:
29110840
6.

Clinical and Pathological Staging Validation in the Eighth Edition of the TNM Classification for Lung Cancer: Correlation between Solid Size on Thin-Section Computed Tomography and Invasive Size in Pathological Findings in the New T Classification.

Aokage K, Miyoshi T, Ishii G, Kusumoto M, Nomura S, Katsumata S, Sekihara K, Hishida T, Tsuboi M.

J Thorac Oncol. 2017 Sep;12(9):1403-1412. doi: 10.1016/j.jtho.2017.06.003. Epub 2017 Jun 13.

PMID:
28627462
7.

CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors.

Ishibashi M, Neri S, Hashimoto H, Miyashita T, Yoshida T, Nakamura Y, Udagawa H, Kirita K, Matsumoto S, Umemura S, Yoh K, Niho S, Tsuboi M, Masutomi K, Goto K, Ochiai A, Ishii G.

Sci Rep. 2017 Apr 21;7:46662. doi: 10.1038/srep46662.

8.

A novel method to generate single-cell-derived cancer-associated fibroblast clones.

Hashimoto H, Suda Y, Miyashita T, Ochiai A, Tsuboi M, Masutomi K, Kiyono T, Ishii G.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1409-1419. doi: 10.1007/s00432-017-2409-3. Epub 2017 Mar 31.

PMID:
28364361
9.

Fibroblast-led cancer cell invasion is activated by epithelial-mesenchymal transition through platelet-derived growth factor BB secretion of lung adenocarcinoma.

Neri S, Miyashita T, Hashimoto H, Suda Y, Ishibashi M, Kii H, Watanabe H, Kuwata T, Tsuboi M, Goto K, Menju T, Sonobe M, Date H, Ochiai A, Ishii G.

Cancer Lett. 2017 Jun 1;395:20-30. doi: 10.1016/j.canlet.2017.02.026. Epub 2017 Mar 9.

PMID:
28286261
10.

Crosstalk Between Cancer Associated Fibroblasts and Cancer Cells in the Tumor Microenvironment After Radiotherapy.

Ishii G.

EBioMedicine. 2017 Mar;17:7-8. doi: 10.1016/j.ebiom.2017.03.004. Epub 2017 Mar 4. No abstract available.

11.

Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation.

Takeuchi S, Fukuda K, Yamada T, Arai S, Takagi S, Ishii G, Ochiai A, Iwakiri S, Itoi K, Uehara H, Nishihara H, Fujita N, Yano S.

Cancer Sci. 2017 Apr;108(4):696-703. doi: 10.1111/cas.13190. Epub 2017 Apr 12.

12.

Single cell time-lapse analysis reveals that podoplanin enhances cell survival and colony formation capacity of squamous cell carcinoma cells.

Miyashita T, Higuchi Y, Kojima M, Ochiai A, Ishii G.

Sci Rep. 2017 Jan 6;7:39971. doi: 10.1038/srep39971.

13.

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.

Yoh K, Seto T, Satouchi M, Nishio M, Yamamoto N, Murakami H, Nogami N, Matsumoto S, Kohno T, Tsuta K, Tsuchihara K, Ishii G, Nomura S, Sato A, Ohtsu A, Ohe Y, Goto K.

Lancet Respir Med. 2017 Jan;5(1):42-50. doi: 10.1016/S2213-2600(16)30322-8. Epub 2016 Nov 4.

PMID:
27825616
14.

Safety of fondaparinux for prevention of postoperative venous thromboembolism in urological malignancy: A prospective randomized clinical trial.

Hata K, Kimura T, Tsuzuki S, Ishii G, Kido M, Yamamoto T, Sasaki H, Miki J, Yamada H, Furuta A, Miki K, Egawa S.

Int J Urol. 2016 Nov;23(11):923-928. doi: 10.1111/iju.13189. Epub 2016 Aug 21.

15.

Clinicopathological significance of caveolin-1 expression by cancer-associated fibroblasts in lung adenocarcinoma.

Shimizu K, Kirita K, Aokage K, Kojima M, Hishida T, Kuwata T, Fujii S, Ochiai A, Funai K, Yoshida J, Tsuboi M, Ishii G.

J Cancer Res Clin Oncol. 2017 Feb;143(2):321-328. doi: 10.1007/s00432-016-2285-2. Epub 2016 Oct 22.

PMID:
27771795
16.

Changes in the tumor microenvironment during lymphatic metastasis of lung squamous cell carcinoma.

Ikemura S, Aramaki N, Fujii S, Kirita K, Umemura S, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Kuwata T, Kojima M, Ochiai A, Betsuyaku T, Tsuboi M, Goto K, Ishii G.

Cancer Sci. 2017 Jan;108(1):136-142. doi: 10.1111/cas.13110. Epub 2017 Jan 21.

17.

Thin-section computed tomography findings of lung adenocarcinoma with inherent metastatic potential.

Suzuki S, Aokage K, Yoshida J, Ishii G, Matsumura Y, Haruki T, Hishida T, Nagai K.

Surg Today. 2017 May;47(5):619-626. doi: 10.1007/s00595-016-1416-3. Epub 2016 Sep 22.

PMID:
27659289
18.

The ratio of cancer cells to stroma after induction therapy in the treatment of non-small cell lung cancer.

Goto M, Naito M, Saruwatari K, Hisakane K, Kojima M, Fujii S, Kuwata T, Ochiai A, Nomura S, Aokage K, Hishida T, Yoshida J, Yokoi K, Tsuboi M, Ishii G.

J Cancer Res Clin Oncol. 2017 Feb;143(2):215-223. doi: 10.1007/s00432-016-2271-8. Epub 2016 Sep 17.

PMID:
27640003
19.

Microenvironmental changes in the progression from adenocarcinoma in situ to minimally invasive adenocarcinoma and invasive lepidic predominant adenocarcinoma of the lung.

Naito M, Aokage K, Saruwatari K, Hisakane K, Miyoshi T, Hishida T, Yoshida J, Masato S, Kojima M, Kuwata T, Fujii S, Ochiai A, Sato Y, Tsuboi M, Ishii G.

Lung Cancer. 2016 Oct;100:53-62. doi: 10.1016/j.lungcan.2016.07.024. Epub 2016 Jul 27.

PMID:
27597281
20.

Non-immune mediated thrombocytopenia caused by thromboprophylaxis for the perioperative care of urological surgery: A case report and review of the literature.

Hata K, Kimura T, Ishii G, Suzuki M, Egawa S.

Int J Surg Case Rep. 2016;27:21-23. doi: 10.1016/j.ijscr.2016.07.049. Epub 2016 Jul 30.

Supplemental Content

Support Center